<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439359</url>
  </required_header>
  <id_info>
    <org_study_id>CF 301-101</org_study_id>
    <nct_id>NCT02439359</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ContraFect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ContraFect</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability
      of Single Intravenous Doses of CF-301 in Healthy Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by AE's</measure>
    <time_frame>up to 8 months</time_frame>
    <description>Safety and tolerability will be assessed by monitoring AEs and performing physical/clinical examinations.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CF-301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF-301</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF-301</intervention_name>
    <description>Dose escalation</description>
    <arm_group_label>CF-301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be a healthy male of any race or ethnicity, at least 18 years of age and no more than
             55 years of age, inclusively, OR

          2. Be a healthy female of any race or ethnicity of non-childbearing potential between 18
             and 55 years of age, inclusive. OR

          3. Be a healthy non-pregnant, non-lactating female of any race or ethnicity of
             childbearing potential between 18 and 55 years of age,

          4. Contraception in use for at least 60 days prior to the Screening visit,

          5. Have a body mass index (BMI) between 18.5 and 32 kg/m2, inclusive

          6. Have no significant diseases in the opinion of the Investigator in the medical history
             or clinically significant findings on physical examination or clinical laboratory
             evaluations.

        Exclusion Criteria:

          1. Any disease or condition in the opinion of the Investigator that might compromise the
             cardiovascular, hematologic, renal, hepatic, pulmonary (including chronic asthma),
             endocrine (eg, diabetes), central nervous, or gastrointestinal (including an ulcer)
             systems.

          2. The presence of clinically significant laboratory values that are out of the normal
             range.

             − Subjects with an aspartate aminotransferase (AST), alanine aminotransferase (ALT),
             gamma-glutamyltransferase (GGT), alkaline phosphatase, bilirubin, blood urea nitrogen
             (BUN), creatinine, prothrombin time (PT), or activated partial thromboplastin time
             (aPTT) &gt; 5% above the upper limit of normal, or hemoglobin or hematocrit level &lt; 5%
             below the lower limit of normal may not be enrolled.

          3. A history of alcoholism or drug addiction, or illicit drug use within the past 2
             years, or positive results from a urine screen for substances of abuse.

          4. Has smoked within 28 days prior to receiving study drug or has a positive urine test
             for cotinine.

          5. A history of serious mental illness.

          6. A history of difficulty donating blood or inadequate venous access.

          7. The donation of blood or plasma within 28 days prior to receiving study drug.

          8. A positive hepatitis screen that tests for both hepatitis B surface antigen (HBsAg)
             and antibody to hepatitis C virus (HCVAb).

          9. A positive test result for human immunodeficiency virus (HIV) antibody by enzyme
             immunoassay, which is confirmed by Western blot.

         10. Use of an investigational drug or product, or participation in a drug study within a
             period of 28 days prior to receiving study drug (for investigational drugs with an
             elimination half-life greater than 10 days, this will be extended to 60 days).

         11. Use of any prescription or over-the-counter (OTC) drug therapy, including herbal,
             homeopathic, vitamins, minerals and nutritional supplements, within 2 weeks prior to
             receiving the study drug contraceptives in women of childbearing potential is allowed
             during the study.

             − If a subject taking prescription drug therapy for chronic diseases, but that
             prescription is stopped in order to qualify for the study, the subject should not be
             enrolled in the study.

         12. Use of any drug therapy (ie, prescription drugs, over-the counter products, herbal and
             vitamin products) known to induce or inhibit cytochrome P450 hepatic enzymes
             responsible for drug metabolism within 28 days prior to receiving study drug or during
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>December 12, 2016</last_update_submitted>
  <last_update_submitted_qc>December 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Public Presentation at ECCMID April 2016</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

